biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Appointment of Shadow Lake Group for Business Development

<< Previous

Bullboard Posts

Next >>

Comment by OysterBuctoucheon Aug 18, 2021 5:16pm

114 Views

Post# 33727662

RE:Appointment of Shadow Lake Group for Business Development

Without knowing anything about Shadow Lake Group i sure like the fact an old partner is back -saving on traing time /education etc and for them to want back feels good relative to our developing science and potential. Financing now enabling new resources from finance to sales to science help to move BTI initiatives along. From the outside looking in there did seem to be a need for cash to enable more resources to move us at a better pace. The next deal will be an interesting point in time for this company

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments